Mirum Pharmaceuticals
biopharmaceutical company
MIRM Nasdaq
ISIN US6047491013 SEC CIK 1759425 LEI 254900YZKR40F7F27K81
Follow Mirum Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$185.7M
+39.6% vs same quarter last year
Net income
−$40.8M
−1503.3% vs same quarter last year
EPS, diluted
−$0.87
−1840% vs same quarter last year
Operating cash flow
−$4.3M
−110.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $521.3M | −$23.4M |
| FY24 | $336.9M | −$87.9M |
| FY23 | $186.4M | −$163.4M |
| FY22 | $77.1M | −$135.7M |
| FY21 | $19.1M | −$84M |
| FY20 | $0 | −$103.3M |
| FY19 | - | −$52.6M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −4.2% | −4.5% |
| FY24 | −26% | −26.1% |
| FY23 | −58.6% | −87.7% |
| FY22 | −170.3% | −176% |
| FY21 | −906.1% | −438.9% |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $54.9M |
| FY24 | $9.3M |
| FY23 | −$71.1M |
| FY22 | −$120.4M |
| FY21 | −$132.8M |
| FY20 | −$89.3M |
| FY19 | −$39.6M |
| FY18 | - |
- Mirum Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Mirum Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −4.5% | −30.6% |
| FY24 | −26.1% | −47% |
| FY23 | −87.7% | −58% |
| FY22 | −176% | −80.4% |
| FY21 | −438.9% | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |